{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:38:59Z","timestamp":1780987139970,"version":"3.54.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15439-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:17:53Z","timestamp":1772180273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer \u2013 a grade-assessed network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Qasi","family":"Najah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0907-4475","authenticated-orcid":false,"given":"Hamdy A.","family":"Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2871-9925","authenticated-orcid":false,"given":"Ahmed S. A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-7059","authenticated-orcid":false,"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1007-5550","authenticated-orcid":false,"given":"Mariam A.","family":"Abusalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-965X","authenticated-orcid":false,"given":"Maaly A.","family":"Abuhlaiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa Ahmed","family":"Qutob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussien Ahmed H.","family":"Abdelgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"15439_CR1","unstructured":"Lung Cancer - Small Cell. Statistics | Cancer.Net. 2024."},{"key":"15439_CR2","unstructured":"SEER*Explorer. An interactive website for SEER cancer statistic. Surveillance Research Program, National Cancer Institute; 2024."},{"key":"15439_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses, and ages. Sci Rep. 2017;7:1339. https:\/\/doi.org\/10.1038\/s41598-017-01571-0.","journal-title":"Sci Rep"},{"key":"15439_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664\u201372. https:\/\/doi.org\/10.1002\/cncr.29098.","journal-title":"Cancer"},{"key":"15439_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(17)30318-2.","journal-title":"Lancet Oncol"},{"key":"15439_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-5002(00)00127-6","volume":"30","author":"C Mascaux","year":"2000","unstructured":"Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lema\u0131\u0302tre F, et al. A systematic review of the role of Etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30:23\u201336. https:\/\/doi.org\/10.1016\/S0169-5002(00)00127-6.","journal-title":"Lung Cancer"},{"key":"15439_CR7","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or Cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.40.4905.","journal-title":"J Clin Oncol"},{"key":"15439_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"A-MC Dingemans","year":"2021","unstructured":"Dingemans A-MC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Ann Oncol"},{"key":"15439_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.lungcan.2010.02.001","volume":"70","author":"A Rossi","year":"2010","unstructured":"Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010;70:119\u201328. https:\/\/doi.org\/10.1016\/j.lungcan.2010.02.001.","journal-title":"Lung Cancer"},{"key":"15439_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-023-36334-1","volume":"14","author":"J Linares","year":"2023","unstructured":"Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, M\u00e9ndez A, Manero-Rup\u00e9rez N, et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nat Commun. 2023;14:746. https:\/\/doi.org\/10.1038\/s41467-023-36334-1.","journal-title":"Nat Commun"},{"key":"15439_CR11","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215\u201322. https:\/\/doi.org\/10.1200\/JCO.2010.29.3423.","journal-title":"J Clin Oncol"},{"key":"15439_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35:1281\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.69.4844.","journal-title":"J Clin Oncol"},{"key":"15439_CR13","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"key":"15439_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"15439_CR15","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"15439_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/jto.0b013e3181d95c87","volume":"5","author":"J Jiang","year":"2010","unstructured":"Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan\/platinum with etoposide\/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5:867\u201373. https:\/\/doi.org\/10.1097\/jto.0b013e3181d95c87.","journal-title":"J Thorac Oncol"},{"key":"15439_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4103\/0973-1482.138002","volume":"12","author":"Q Hu","year":"2016","unstructured":"Hu Q, Wang Q, Zhu H, Yao Y, Song Q. Irinotecan compared with etoposide in combination with platinum in previously untreated extensive stage small cell lung cancer: an updated systemic review. J Cancer Res Ther. 2016;12:881\u20137. https:\/\/doi.org\/10.4103\/0973-1482.138002.","journal-title":"J Cancer Res Ther"},{"key":"15439_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12723","volume":"26","author":"D Han","year":"2017","unstructured":"Han D, Wang G, Sun L, Ren X, Shang W, Xu L, et al. Comparison of irinotecan\/platinum versus etoposide\/platinum chemotherapy for extensive-stage small cell lung cancer: a meta-analysis. Eur J Cancer Care (Engl). 2017;26:e12723. https:\/\/doi.org\/10.1111\/ecc.12723.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"15439_CR19","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.2 [updated February 2021] Cochrane","year":"2021","unstructured":"Higgins JPT, Green S, Cochrane C, editors. Cochrane handbook for systematic reviews of interventions version 6.2 [updated February 2021] Cochrane. Hoboken, NJ: Wiley-Blackwell;: Chichester, England; 2021."},{"key":"15439_CR20","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"15439_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","journal-title":"BMC Health Serv Res"},{"key":"15439_CR22","unstructured":"Plot, Digitizer. Free Software Foundation, Boston, MA, USA). 2025."},{"key":"15439_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"15439_CR24","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"15439_CR25","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. 2024."},{"key":"15439_CR26","doi-asserted-by":"publisher","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. Netmeta: an R package for network Meta-Analysis using frequentist methods. J Stat Softw. 2023;106. https:\/\/doi.org\/10.18637\/jss.v106.i02.","DOI":"10.18637\/jss.v106.i02"},{"key":"15439_CR27","doi-asserted-by":"publisher","unstructured":"Wickham H. ggplot2., Cham. Springer International Publishing; 2016. https:\/\/doi.org\/10.1007\/978-3-319-24277-4.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"15439_CR28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"15439_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015.","journal-title":"J Clin Epidemiol"},{"key":"15439_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074495","volume":"381","author":"A Izcovich","year":"2023","unstructured":"Izcovich A, Chu DK, Mustafa RA, Guyatt G, Brignardello-Petersen R. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ. 2023;e074495. https:\/\/doi.org\/10.1136\/bmj-2022-074495.","journal-title":"BMJ"},{"key":"15439_CR31","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.ccr-20-4259","volume":"27","author":"LA Byers","year":"2021","unstructured":"Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, et al. Veliparib in combination with Carboplatin and Etoposide in patients with Treatment-Na\u00efve Extensive-Stage Small Cell Lung Cancer: a phase 2 randomized study. Clin Cancer Res. 2021;27:3884\u201395. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4259.","journal-title":"Clin Cancer Res"},{"key":"15439_CR32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with Extensive-Stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328:1223. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"key":"15439_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus Platinum and Etoposide versus Placebo plus Platinum and Etoposide as first-line treatment for Extensive-Stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19:1073\u201385. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008.","journal-title":"J Thorac Oncol"},{"key":"15439_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 extentorch randomized clinical trial. JAMA Oncol. 2025;11:16. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5019.","journal-title":"JAMA Oncol"},{"key":"15439_CR35","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/jco.2005.03.3332","volume":"24","author":"JR Eckardt","year":"2006","unstructured":"Eckardt JR, Von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan\/cisplatin versus etoposide\/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044\u201351. https:\/\/doi.org\/10.1200\/jco.2005.03.3332.","journal-title":"J Clin Oncol"},{"key":"15439_CR36","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1097\/jto.0b013e318260de75","volume":"7","author":"TH Fink","year":"2012","unstructured":"Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan\/cisplatin compared with cisplatin\/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7:1432\u20139. https:\/\/doi.org\/10.1097\/jto.0b013e318260de75.","journal-title":"J Thorac Oncol"},{"key":"15439_CR37","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/jco.2005.04.8595","volume":"24","author":"N Hanna","year":"2006","unstructured":"Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038\u201343. https:\/\/doi.org\/10.1200\/jco.2005.04.8595.","journal-title":"J Clin Oncol"},{"key":"15439_CR38","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/jco.2007.15.7545","volume":"26","author":"A Hermes","year":"2008","unstructured":"Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26:4261\u20137. https:\/\/doi.org\/10.1200\/jco.2007.15.7545.","journal-title":"J Clin Oncol"},{"key":"15439_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4143\/crt.2018.019","volume":"51","author":"D-W Kim","year":"2019","unstructured":"Kim D-W, Kim H-G, Kim J-H, Park K, Kim H-K, Jang JS, et al. Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-na\u00efve Korean patients with extensive-disease small cell lung cancer. Cancer Res Treat. 2019;51:119\u201327. https:\/\/doi.org\/10.4143\/crt.2018.019.","journal-title":"Cancer Res Treat"},{"key":"15439_CR40","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/0284186x.2023.2278173","volume":"62","author":"M Mau-S\u00f8rensen","year":"2023","unstructured":"Mau-S\u00f8rensen M, Gerner-Rasmussen J, Hansen O, Holm B, Nyhus CH, McCulloch T, et al. Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan. Acta Oncol. 2023;62:1979\u201382. https:\/\/doi.org\/10.1080\/0284186x.2023.2278173.","journal-title":"Acta Oncol"},{"key":"15439_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2017.06.016","volume":"111","author":"N Morikawa","year":"2017","unstructured":"Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, et al. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-na\u00efve extensive-stage small-cell lung cancer: North Japan lung cancer study group (NJLCG) 0901. Lung Cancer. 2017;111:38\u201342. https:\/\/doi.org\/10.1016\/j.lungcan.2017.06.016.","journal-title":"Lung Cancer"},{"key":"15439_CR42","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.ejca.2011.05.020","volume":"47","author":"MER O\u2019Brien","year":"2011","unstructured":"O\u2019Brien MER, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer \u2013 EORTC 08062. Eur J Cancer. 2011;47:2322\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2011.05.020.","journal-title":"Eur J Cancer"},{"key":"15439_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00280-013-2338-z","volume":"73","author":"TK Owonikoko","year":"2014","unstructured":"Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, et al. E5501: phase II study of Topotecan sequenced with Etoposide\/cisplatin, and irinotecan\/cisplatin sequenced with Etoposide for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2014;73:171\u201380. https:\/\/doi.org\/10.1007\/s00280-013-2338-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"15439_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/jco.18.00264","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL, Srkalovic G, et al. Randomized phase II trial of Cisplatin and Etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37:222\u20139. https:\/\/doi.org\/10.1200\/jco.18.00264.","journal-title":"J Clin Oncol"},{"key":"15439_CR45","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408.","journal-title":"ESMO Open"},{"key":"15439_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2005.02.008","volume":"49","author":"E Quoix","year":"2005","unstructured":"Quoix E, Breton J-L, Gervais R, Wilson J, Schramel F, Cardenal F, et al. A randomised phase II study of the efficacy and safety of intravenous Topotecan in combination with either cisplatin or Etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer. 2005;49:253\u201361. https:\/\/doi.org\/10.1016\/j.lungcan.2005.02.008.","journal-title":"Lung Cancer"},{"key":"15439_CR47","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/jco.2016.67.6601","volume":"34","author":"M Reck","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W, et al. Phase III randomized trial of Ipilimumab plus Etoposide and Platinum versus placebo plus Etoposide and Platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740\u20138. https:\/\/doi.org\/10.1200\/jco.2016.67.6601.","journal-title":"J Clin Oncol"},{"key":"15439_CR48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jtho.2019.01.010","volume":"14","author":"M Reck","year":"2019","unstructured":"Reck M, Horn L, Novello S, Barlesi F, Albert I, Juh\u00e1sz E, et al. Phase II study of Roniciclib in combination with Cisplatin\/Etoposide or Carboplatin\/Etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J Thorac Oncol. 2019;14:701\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.010.","journal-title":"J Thorac Oncol"},{"key":"15439_CR49","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/jco.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee J-S, et al. SKYSCRAPER-02: tiragolumab in combination with Atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2024;42:324\u201335. https:\/\/doi.org\/10.1200\/jco.23.01363.","journal-title":"J Clin Oncol"},{"key":"15439_CR50","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/jco.2013.53.5153","volume":"32","author":"M Satouchi","year":"2014","unstructured":"Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014;32:1262\u20138. https:\/\/doi.org\/10.1200\/jco.2013.53.5153.","journal-title":"J Clin Oncol"},{"key":"15439_CR51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/annonc\/mdj137","volume":"17","author":"A Schmittel","year":"2006","unstructured":"Schmittel A, Von Weikersthal LF, Sebastian M, Martus P, Schulze K, Hortig P, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006;17:663\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdj137.","journal-title":"Ann Oncol"},{"key":"15439_CR52","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/annonc\/mdq652","volume":"22","author":"A Schmittel","year":"2011","unstructured":"Schmittel A, Sebastian M, Fischer Von Weikersthal L, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan\u2013carboplatin with etoposide\u2013carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011;22:1798\u2013804. https:\/\/doi.org\/10.1093\/annonc\/mdq652.","journal-title":"Ann Oncol"},{"key":"15439_CR53","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.bjc.6604233","volume":"98","author":"I Sekine","year":"2008","unstructured":"Sekine I, Nokihara H, Takeda K, Nishiwaki Y, Nakagawa K, Isobe H, et al. Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer. Br J Cancer. 2008;98:693\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6604233.","journal-title":"Br J Cancer"},{"key":"15439_CR54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cllc.2013.11.006","volume":"15","author":"I Sekine","year":"2014","unstructured":"Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, et al. A randomized phase III study of single-agent amrubicin vs. carboplatin\/etoposide in elderly patients with extensive-disease small-cell lung cancer. Clin Lung Cancer. 2014;15:96\u2013102. https:\/\/doi.org\/10.1016\/j.cllc.2013.11.006.","journal-title":"Clin Lung Cancer"},{"key":"15439_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/1759-7714.12303","volume":"6","author":"Y Shi","year":"2015","unstructured":"Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6:785\u201391. https:\/\/doi.org\/10.1111\/1759-7714.12303.","journal-title":"Thorac Cancer"},{"key":"15439_CR56","doi-asserted-by":"publisher","first-page":"107195","DOI":"10.1016\/j.lungcan.2023.107195","volume":"181","author":"T Shimokawa","year":"2023","unstructured":"Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, et al. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: a phase II\/III randomized control trial. Lung Cancer. 2023;181:107195. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107195.","journal-title":"Lung Cancer"},{"key":"15439_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2301-6","author":"Y Sun","year":"2016","unstructured":"Sun Y, Cheng Y, Hao X, Wang J, Hu C, Han B, et al. Randomized phase III trial of amrubicin\/cisplatin versus etoposide\/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016. https:\/\/doi.org\/10.1186\/s12885-016-2301-6.","journal-title":"BMC Cancer"},{"key":"15439_CR58","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/annonc\/mdq036","volume":"21","author":"P Zatloukal","year":"2010","unstructured":"Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21:1810\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdq036.","journal-title":"Ann Oncol"},{"key":"15439_CR59","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"key":"15439_CR60","unstructured":"Dissecting the mechanisms of immune checkpoint therapy | Nature Reviews Immunology. https:\/\/www.nature.com\/articles\/s41577-020-0275-8. Accessed 15 May 2025."},{"key":"15439_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with Extensive-Stage Small-Cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01055.","journal-title":"J Clin Oncol"},{"key":"15439_CR62","unstructured":"Lu J, Lei X, Zhang P, Du L, Zhang Z, Qu B. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer. PubMed."},{"key":"15439_CR63","doi-asserted-by":"publisher","unstructured":"Ying Cheng L, Han L, Wu J, Chen H, Sun G, Wen et al. Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study. J Clin Oncol. 2024;42 16_suppl:8100\u20138100. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8100.","DOI":"10.1200\/JCO.2024.42.16_suppl.8100"},{"key":"15439_CR64","doi-asserted-by":"crossref","unstructured":"Zhang B, Chen J, Yu H, Li M, Chen L. Adding immune checkpoint inhibitors to chemotherapy confers modest survival benefit in patients with small cell lung cancer and brain metastases: a retrospective analysis. PubMed. 2024.","DOI":"10.21037\/tlcr-24-335"},{"key":"15439_CR65","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1002\/cam4.5750","volume":"12","author":"G Lin","year":"2023","unstructured":"Lin G, Yao Z, Kang K, Wang H, Luo R, Lu Y. Efficacy and toxicity profile of first-line treatment for extensive\u2010stage small cell lung cancer: a bayesian network meta\u2010analysis. Cancer Med. 2023;12:10230\u201342. https:\/\/doi.org\/10.1002\/cam4.5750.","journal-title":"Cancer Med"},{"key":"15439_CR66","doi-asserted-by":"publisher","first-page":"1362537","DOI":"10.3389\/fimmu.2024.1362537","volume":"15","author":"S Gong","year":"2024","unstructured":"Gong S, Li Q, Yu X, Yang S. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis. Front Immunol. 2024;15:1362537. https:\/\/doi.org\/10.3389\/fimmu.2024.1362537.","journal-title":"Front Immunol"},{"key":"15439_CR67","doi-asserted-by":"crossref","unstructured":"Zhu Y, Liu K, Qin Q, Zhu H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. PubMed. 2023.","DOI":"10.3389\/fimmu.2022.1044678"},{"key":"15439_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055","author":"Sv Liu","year":"2021","unstructured":"Liu Sv, Reck M, Mansfield As, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.20.01055.","journal-title":"J Clin Oncol"},{"key":"15439_CR69","unstructured":"Guidelines Detail. NCCN. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462. Accessed 10 May 2025."},{"key":"15439_CR70","unstructured":"Goldman Jw, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. PubMed."},{"key":"15439_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"15439_CR72","doi-asserted-by":"publisher","unstructured":"Yu Saida T, Asao S, Watanabe A, Kisohara K, Kishi R, Morita et al. Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study). J Clin Oncol. 2024;42 16_suppl:8101\u20138101. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8101","DOI":"10.1200\/JCO.2024.42.16_suppl.8101"},{"key":"15439_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4715-9","author":"F Xu","year":"2018","unstructured":"Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y, et al. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC Cancer. 2018. https:\/\/doi.org\/10.1186\/s12885-018-4715-9.","journal-title":"BMC Cancer"},{"key":"15439_CR74","unstructured":"Project information | Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Guidance | NICE. 2025. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11405. Accessed 10 May 2025."},{"key":"15439_CR75","doi-asserted-by":"crossref","unstructured":"ESMO, Guidelines. May. https:\/\/www.esmo.org\/guidelines. Accessed 10 2025.","DOI":"10.1016\/S2059-7029(25)01399-7"},{"key":"15439_CR76","doi-asserted-by":"publisher","first-page":"1455306","DOI":"10.3389\/fonc.2024.1455306","volume":"14","author":"K Wang","year":"2024","unstructured":"Wang K, Zheng C, Chen X, Lin P, Lin M, Chen C, et al. Updated bayesian network meta-analysis on the efficacy and safety of PD-1 versus PD-L1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Front Oncol. 2024;14:1455306. https:\/\/doi.org\/10.3389\/fonc.2024.1455306.","journal-title":"Front Oncol"},{"key":"15439_CR77","first-page":"493","volume-title":"Cochrane Handb Syst Rev Interv","author":"G Peryer","year":"2019","unstructured":"Peryer G, Golder S, Junqueira DR, Vohra S, Loke YK, Cochrane Adverse Effects Methods Group. Adverse effects. In: Cochrane Handb Syst Rev Interv. 2019. p. 493\u2013505."},{"key":"15439_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13804","volume":"18","author":"W Liu","year":"2024","unstructured":"Liu W, Yu L, Feng Y, Huang S, Hua Y, Peng M, et al. Which is more suitable for first-line treatment of extensive-stage small cell lung cancer, PD-L1 inhibitors versus PD-1 inhibitors? A systematic review and network meta-analysis. Clin Respir J. 2024;18:e13804. https:\/\/doi.org\/10.1111\/crj.13804.","journal-title":"Clin Respir J"},{"key":"15439_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds213","author":"M Reck","year":"2013","unstructured":"Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial\u2020. Ann Oncol. 2013. https:\/\/doi.org\/10.1093\/annonc\/mds213.","journal-title":"Ann Oncol"},{"key":"15439_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00228-024-03789-0","volume":"81","author":"Q Najah","year":"2025","unstructured":"Najah Q, Almosilhy NA, Ghanm TIE. Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? A meta-analysis. Eur J Clin Pharmacol. 2025;81:269\u201378. https:\/\/doi.org\/10.1007\/s00228-024-03789-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"15439_CR81","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/1759-7714.15310","volume":"15","author":"T Chuang Yang","year":"2024","unstructured":"Chuang Yang T, Xuan Q, Gong X, Dai C, Wang R, Zhang, et al. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis. Thorac Cancer. 2024;15:1246\u201362. https:\/\/doi.org\/10.1111\/1759-7714.15310.","journal-title":"Thorac Cancer"},{"key":"15439_CR82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12890-025-03479-2","volume":"25","author":"Z Linfeng Wang, Guangda","year":"2025","unstructured":"Linfeng Wang, Guangda Z, Yue H, Maolan A, Luo Y, Li Y, et al. Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis. BMC Pulm Med. 2025;25:49. https:\/\/doi.org\/10.1186\/s12890-025-03479-2.","journal-title":"BMC Pulm Med"},{"key":"15439_CR83","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1002\/cncr.25532","volume":"116","author":"PN Lara","year":"2010","unstructured":"Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, et al. Common arm comparative outcomes analysis of phase III trials of cisplatin\u2009+\u2009irinotecan vs. cisplatin\u2009+\u2009etoposide in extensive stage small cell lung cancer: final patient-level results from JCOG 9511 and SWOG 0124. Cancer. 2010;116:5710\u20135. https:\/\/doi.org\/10.1002\/cncr.25532.","journal-title":"Cancer"},{"key":"15439_CR84","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"Y Kazumasa Noda","year":"2002","unstructured":"Kazumasa Noda Y, Nishiwaki M, Kawahara S, Negoro T, Sugiura A, Yokoyama, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive Small-Cell lung cancer. N Engl J Med. 2002;346:85\u201391. https:\/\/doi.org\/10.1056\/NEJMoa003034.","journal-title":"N Engl J Med"},{"key":"15439_CR85","doi-asserted-by":"crossref","unstructured":"Dr S, Pm T, Dm W, Je LFIA. H, Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. PubMed. 2011.","DOI":"10.1016\/j.yonc.2011.07.025"},{"key":"15439_CR86","unstructured":"Jl P, E AL, O Q, Pj M. S, F B, Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial\u2020. PubMed."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15439-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:00:29Z","timestamp":1772449229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15439-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15439"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15439-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and network meta-analysis of previously published randomized controlled trials and did not involve the collection of new human or animal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}